

1 **Evaluation of accuracy, exclusivity, limit-of-detection and ease-of-use of LumiraDx™**

2 -

3 **Antigen-detecting point-of-care device for SARS-CoV-2**

4
5
6 Lisa J. Krüger ^a, Julian A.F. Klein ^a, Frank Tobian ^a, Mary Gaeddert ^a, Federica Lainati ^a, Sarah Klemm ^b, Paul Schnitzler
7 ^b, Ralf Bartenschlager ^{c,l}, Berati Cerikan ^c, Christopher J. Neufeldt ^c, Olga Nikolai ^d, Andreas K. Lindner ^d, Frank P.
8 Mockenhaupt ^d, Joachim Seybold ^e, Terry C. Jones ^{f,g,h}, Victor M. Corman ^{f,g}, Nira R. Pollock ⁱ, Britta Knorr ^j, Andreas
9 Welker ^j, Margaretha de Vos ^k, Jilian A. Sacks ^k, Claudia M. Denkinger ^{a,l,#} for the study team [&]

10 ^a. Division of Clinical Tropical Medicine, Heidelberg University Hospital, Heidelberg, Germany

11 ^b. Virology, Heidelberg University Hospital, Heidelberg, Germany

12 ^c. Department of Infectious Diseases, Molecular Virology, Centre for Integrative Infectious Diseases Research (CIID),
13 Heidelberg University Hospital, Heidelberg, Germany

14 ^d. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu
15 Berlin, and Berlin Institute of Health; Institute of Tropical Medicine and International Health, Berlin, Germany

16 ^e. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu
17 Berlin, and Berlin Institute of Health; Medical Directorate, Berlin, Germany

18 ^f. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu
19 Berlin, and Berlin Institute of Health; Institute of Virology, Berlin, Germany

20 ^g. German Centre for Infection Research (DZIF), partner site Charité, Berlin, Germany

21 ^h. Centre for Pathogen Evolution, Department of Zoology, University of Cambridge, Cambridge, UK.

22 ⁱ. Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA, USA

23 ^j. Department of Public Health Rhein Neckar Region, Germany

24 ^k. Foundation for Innovative New Diagnostics, Geneva, Switzerland

25 ^l. German Centre for Infection Research (DZIF), partner site Heidelberg University Hospital, Heidelberg, Germany

26 **Running title:** Evaluation of LumiraDx™, diagnostic for SARS-CoV-2

27
28 [#]Address correspondence to Claudia M. Denkinger, claudia.Denkinger@uni-heidelberg.de

29
30

31 **Abstract**

32 **Background:** Rapid antigen-detecting tests (Ag-RDTs) for severe acute respiratory syndrome
33 coronavirus 2 (*SARS-CoV-2*) can transform pandemic control. Thus far, sensitivity ($\leq 85\%$) of
34 lateral-flow assays has limited scale-up. Conceivably, microfluidic immunofluorescence Ag-RDTs
35 could increase sensitivity for *SARS-CoV-2* detection.

36 **Materials and Methods:** This multi-centre diagnostic accuracy study investigated performance
37 of the microfluidic immunofluorescence LumiraDx™ assay, enrolling symptomatic and
38 asymptomatic participants with suspected *SARS-CoV-2* infection. Participants collected a
39 supervised nasal mid-turbinate (NMT) self-swab for Ag-RDT testing, in addition to a
40 professionally-collected nasopharyngeal (NP) swab for routine testing with reverse transcriptase
41 polymerase chain reaction (RT-PCR). Results were compared to calculate sensitivity and
42 specificity. Sub-analyses investigated the results by viral load, symptom presence and duration.
43 An analytical study assessed exclusivity and limit-of-detection (LOD). In addition, we evaluated
44 ease-of-use.

45 **Results:** Study conduct was between November 2nd 2020 and January 21st 2021. 761
46 participants were enrolled, with 486 participants reporting symptoms on testing day. 120 out of
47 146 RT-PCR positive cases were detected positive by LumiraDx™, resulting in a sensitivity of
48 82.2% (95% CI: 75.2%-87.5%). Specificity was 99.3% (CI: 98.3-99.7%). Sensitivity was increased in
49 individuals with viral load ≥ 7 log₁₀ SARS-CoV2 RNA copies/ml (93.8%; CI: 86.2%-97.3%). Testing
50 against common respiratory commensals and pathogens showed no cross-reactivity and LOD

51 was estimated to be 2-56 PFU/mL. The ease-of-use-assessment was favourable for lower
52 throughput settings.

53 **Conclusion:** The LumiraDx™ assay showed excellent analytical sensitivity, exclusivity and clinical
54 specificity with good clinical sensitivity using supervised NMT self-sampling.

55 Introduction

56 The SARS-CoV-2 pandemic has caused over 100 million confirmed infections worldwide, stated
57 by the World Health Organization (WHO) (<https://covid19.who.int/>). Reverse transcriptase
58 polymerase chain reaction (RT-PCR) has been established as the gold standard for diagnosing
59 individuals infected with SARS-CoV-2 (1). Because RT-PCR testing requires advanced laboratory
60 infrastructure demanding numerous predefined materials and specially-trained staff, testing
61 capacities in many countries have at times been pushed to their limits. Also, the longer turn-
62 around time for results from laboratory-based RT-PCR testing does not allow for rapid decision-
63 making, often taking days until results are available, thus identifying infected individuals often
64 too late to prevent secondary cases, expressed by the WHO
65 ([https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020)
66 [media-briefing-on-covid-19---16-march-2020](https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---16-march-2020)).

67 SARS-CoV-2 rapid antigen-detecting tests (Ag-RDTs) can be considered complementary to RT-
68 PCR for rapid testing, or as an alternative for RT-PCR in settings where resources and laboratory
69 infrastructure are limited as suggested by the WHO ([https://www.who.int/news-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)
70 [room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)
71 [covid-19](https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-immunodiagnostic-tests-for-covid-19)). Several countries are incorporating these tests into their national testing strategies
72 and some (e.g. Slovakia and the United Kingdom) are utilizing them for large scale screening (2).
73 Most tests on the market use the lateral flow principle, gathered and explained by the
74 Foundation of Innovative New Diagnostics (FIND) (<https://www.finddx.org/covid-19/pipeline/>).
75 While many tests have shown excellent specificity, sensitivity in several independent
76 evaluations has been around 85% or less (<https://diagnosticsglobalhealth.org/> (3-5)).

77 Conceivably, microfluidic immunofluorescence combined with digital result capture and
78 connectivity could boost sensitivity and ease of use of Ag-RDTs (6).

79 LumiraDx™ has recently developed a diagnostic device using microfluidic immunofluorescence
80 technology with automated read-out to enable rapid detection of SARS-CoV-2 antigen from a
81 nasal mid-turbinate (NMT) swab ([https://www.lumiradx.com/uk-en/what-we-](https://www.lumiradx.com/uk-en/what-we-do/diagnostics/test-technology/antigen-test)
82 [do/diagnostics/test-technology/antigen-test](https://www.lumiradx.com/uk-en/what-we-do/diagnostics/test-technology/antigen-test)). In the United States, the LumiraDx™ SARS-CoV-2
83 Ag-RDT was granted an emergency use authorization by the Federal Drug Agency (FDA) in
84 August 2020 ([https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization)
85 [regulatory-and-policy-framework/emergency-use-authorization](https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization)). In the United Kingdom, a large
86 pharmacy chain offers LumiraDx™ SARS-CoV-2 testing at the point-of-care ([https://www.boots-](https://www.boots-uk.com/media-centre/press-releases/new-covid-19-testing-service-now-available-in-boots-uk-stores/)
87 [uk.com/media-centre/press-releases/new-covid-19-testing-service-now-available-in-boots-uk-](https://www.boots-uk.com/media-centre/press-releases/new-covid-19-testing-service-now-available-in-boots-uk-stores/)
88 [stores/](https://www.boots-uk.com/media-centre/press-releases/new-covid-19-testing-service-now-available-in-boots-uk-stores/)). To date, there is only one publication available, sponsored by the manufacturer, that
89 reported a 97.6% sensitivity and 96.6% specificity (7) in nasal swabs from mostly symptomatic
90 persons within 12 days of symptom onset.

91 This multi-centre, manufacturer-independent diagnostic accuracy study investigated the
92 performance, ease-of-use, exclusivity, and limit-of-detection of the microfluidic
93 immunofluorescence SARS-CoV-2 LumiraDx™ antigen test (henceforth called LumiraDx™).

94 **Materials and Methods**

95 **Index Test**

96 The diagnostic test under evaluation in this study was the microfluidic immunofluorescence
97 assay, *SARS-CoV-2* Ag test developed by LumiraDx™ Limited, London, United Kingdom
98 (henceforth called LumiraDx™). The assay runs on a portable platform using a dry, single-use,
99 disposable, microfluidic test strip. The strip incorporates antibodies specific to the nucleocapsid
100 protein of *SARS-CoV-2*, that, in combination with magnetic particles, form a sandwich-like
101 immuno-complex that emits a fluorescent latex signal ([https://www.lumiradx.com/uk-en/what-we-](https://www.lumiradx.com/uk-en/what-we-do/diagnostics/test-technology/antigen-test)
102 [do/diagnostics/test-technology/antigen-test](https://www.lumiradx.com/uk-en/what-we-do/diagnostics/test-technology/antigen-test)).

103 The sample collection was performed with Dryswab™ Standard Tip Rayon (Medical Wire &
104 Equipment, Corsham, England), not included in the test kits, but recommend for use by the
105 manufacturer. Ag-RDT testing was performed on-site in a dedicated workspace, that was
106 divided into separate areas where infectious and non-infectious materials were handled.
107 Laboratory personal for Ag-RDT testing was blinded to the results of RT-PCR testing and vice
108 versa. Following manufacturer instructions for use, the collected sample was processed using
109 the LumiraDx™ proprietary extraction buffer vial for ten seconds. A single-use test strip was
110 placed in the designated slot on the testing device, and one drop (~ 20 µL) of the prepared
111 extraction buffer solution was applied. The device was closed to initiate automatic processing
112 and testing. The device showed a qualitative result (“positive”, “negative” or “error”) on the
113 digital touch screen within twelve minutes. In case of an erroneous test result, the testing was
114 immediately repeated using the solution from the same extraction vial and a new test strip.

115 For every test, a cut-off-index (COI) value was automatically generated and documented in the
116 testing device, reporting the test immunofluorescent signal on a continuous scale with a pre-set

117 cut-off categorizing the results as positive or negative. COI values were retrieved from the test
118 devices by the manufacturer after completion of the study. The device can operate in a cloud-
119 based mode enabling the manufacturer to receive all impersonal data through an online
120 connection. During this study, the manufacturer could not access the device as the study was
121 performed offline.

122 After every test, the surface of the device was disinfected with proprietary disinfection wipes
123 provided by the company. A five-minute drying time was recommended before the next sample
124 was inserted, following the manufacturer information for use ([https://www.lumiradx.com/uk-
125 en/what-we-do/diagnostics/test-technology/antigen-test](https://www.lumiradx.com/uk-en/what-we-do/diagnostics/test-technology/antigen-test)).

126 **Reference test**

127 Reverse transcriptase-polymerase chain reaction (RT-PCR) was used as the reference test. The
128 RT-PCR samples were collected by health-care workers using the IMPROSWAB® (Guangzhou
129 Improve Medical Instruments Co., Ltd., Guangzhou, China) at the Heidelberg study site and the
130 eSwab™ (Copan Diagnostics Inc., Murrieta, CA, USA) at the study site in Berlin. Collected
131 samples were transferred to the referral laboratories for RT-PCR testing in Heidelberg and
132 Berlin. The RT-PCR assays, referral laboratory standard assays, used for clinical diagnosis as
133 comparators were Allplex™ SARS-CoV-2 assay (Seegene, Seoul, South Korea) in Heidelberg and
134 cobas™ SARS CoV-2 assay on the cobas® 6800 or 8800 system (Roche, Pleasanton, CA, United
135 States) or the SARS CoV-2 assay from TIB Molbiol (Berlin, Germany) in Berlin. Interpretation of
136 the RT-PCR assays followed the manufacturers' instructions. The RT-PCR assays targeted the E
137 gene of SARS-CoV-2, which was used for the CT-value determination and the viral load
138 calculations. Based on testing of standardized material, CT-values of the three tests are

139 expected to differ by around 2-3 with the same amount of virus present [2]. The conversion of
140 CT-values into viral-load was based on calibrated RT-PCR testing with quantified SARS-CoV-2 in
141 vitro transcripts [2].

142 **Clinical diagnostic accuracy**

143 The standards for reporting diagnostic accuracy studies (STARD) were followed for reporting of
144 this study (8).

145 Study design and inclusion criteria

146 This prospective multi-centre study enrolled participants at two sites, Heidelberg and Berlin,
147 Germany. In Heidelberg, participants were enrolled at a drive-in testing site whereas in Berlin
148 participants were enrolled at a clinical ambulatory testing facility. All participants were
149 identified for testing according to the criteria of the national health authority as being at risk of
150 SARS-CoV-2 infection based on reported symptoms or recent contact with a confirmed case
151 ([https://www.rki.de/DE/Content/InfAZ/N/Neuartiges Coronavirus/Teststrategie/Testkriterien](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Teststrategie/Testkriterien_Herbst_Winter.html)
152 [Herbst_Winter.html](https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Teststrategie/Testkriterien_Herbst_Winter.html)). Inclusion criteria were a minimum age of 18 years and no prior positive
153 RT-PCR result for SARS-CoV-2. Written informed consent was obtained from each participant
154 prior to testing. Individuals unable to give written informed consent due to limited command of
155 German or English were excluded from the study. The study protocol is available upon request.

156 Sample collection

157 The sample for the Ag-RDT was a NMT, following the definition from the Centers for Disease
158 Control and Prevention ([https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html#specimen)
159 [specimens.html#specimen](https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html#specimen)). This swab was collected by the participants themselves, with a

160 health-care worker providing instructions, supervision and corrections according to the
161 instruction for use by the manufacturer. The participants were instructed to tilt their head back
162 70 degrees, insert the swab approximately 2cm into one nostril, and to rotate it several times
163 against the full interior nasal wall surface for at least 10 seconds. The identical procedure was
164 repeated with the same swab in the contralateral nostril.
165 Subsequently, the professional-collected routine swab for RT-PCR testing was taken, following
166 institutional procedures with a nasopharyngeal (NP) swab (Heidelberg) or a combined
167 NP/oropharyngeal (OP) swab (Berlin). Participants underwent OP swabbing only if there were
168 clinical contraindications for NP sampling.

169 Questionnaire

170 All participants were asked for information on comorbidities, symptom presence and duration,
171 and severity of disease (questionnaire available in the supplement material, Section (A)). For
172 data collection, we used the Research Electronic Data Capture (REDCap) tools hosted at
173 Heidelberg University (9).

174 RT-PCR from Ag-RDT extraction buffer

175 All false-positive and false-negative Ag-RDT results were retested with RT-PCR from the Ag-RDT
176 proprietary buffer solution that was stored at a temperature of -20°C if sufficient volume was
177 available. This testing is not validated by the manufacturer but was performed to resolve
178 discrepant results that could have occurred due to variability between the NP and NMT
179 sampling for RT-PCR and Ag-RDT. To avoid the introduction of a discrepant analysis bias, a

180 subset of samples (first 5 per day in the first 2 weeks) was also re-tested with RT-PCR from the
181 antigen buffer.

182 **Exclusivity testing**

183 Clinical samples from common respiratory tract pathogens or commensals were assessed for
184 cross-reactivity. The respiratory swab samples contained coronavirus, adenovirus, bocavirus,
185 influenza virus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus or
186 *Mycoplasma pneumoniae* as identified by RT-PCR in the laboratory. For *Staphylococcus aureus*
187 and *Streptococcus sp.* swab samples from bacterial culture were utilized. As recommended by
188 the manufacturer these samples were added to the extraction buffer in a 1:10 dilution (30µl
189 sample and 270µl extraction buffer) and processed according to the standard test protocol.

190 **Limit-of-detection assay using cell culture-grown SARS-CoV-2**

191 The BavPat1/2020 strain was kindly provided by Christian Drosten through the European Virus
192 Archive and the HD strain was isolated from a patient at the Heidelberg clinic. Working virus
193 stocks were generated by passaging the virus two times in VeroE6 cells or Calu3 cells (a kind gift
194 from Dr. Manfred Frey, Mannheim). Virus stocks were tittered using a plaque forming unit (PFU)
195 assay (10). The stock was pre-diluted in DMEM supplemented with 2% FCS to 10000 PFU/mL.
196 Then two-fold dilutions were generated and added 1:1 to the isolation buffer provided for each
197 test kit. Following this, the manufacturer's protocol for each kit was used. Note, that the
198 amount of volume used for each kit was slightly different according to the protocols (50µL for
199 Abbott PanBio, 100µL for Biosensor Standard Q and 35µL for LumiraDx™). The limit of detection

200 was calculated based on the number of PFUs in this volume. Three replicates were done for
201 each dilution.

202 **System Usability Scale and Ease-of-Use Assessment**

203 To determine and quantify the usability of the test, a standardized System Usability Scale (SUS)
204 questionnaire was used and a dedicated ease-of-use assessment (EoU) was developed. The
205 detailed surveys are provided in the supplement material (Section (B) and (C)). Staff performing
206 the testing at both study sites were invited to complete the questionnaires. A SUS score above
207 68 is interpreted as above average (11). For the visualization of the EoU assessment a colour-
208 coded rating (heat-map) was generated. Each aspect of the assessment was ranked as
209 satisfactory, average, or unsatisfactory. The supplement material (Section (D)) shows the matrix
210 used for this analysis.

211 **Statistics**

212 To determine sensitivity and specificity of the Ag-RDT (with 95% CIs), results were compared to
213 RT-PCR results from the same participant, as per Altman (12). Predefined sub-analyses were
214 conducted for presence of symptoms, duration of symptoms (≤ 7 , > 7 days and > 12 days), CT-
215 values (using two categorizations: ≤ 25 , > 25 and ≤ 30 , > 30), viral load, and study site. A two-sided
216 alpha value of 0.05 was defined as a significance cut-off. We used “R” version 4.0.3. (R
217 Foundation for Statistical Computing, Vienna, Austria) to generate all analyses and plots.

218 **Study approval**

219 The study protocol was approved in March 2020 by the ethical review committee at the
220 Heidelberg University Hospital for the two study sites Heidelberg and Berlin in Germany
221 (Registration number S-180/2020). All participants provided written informed consent prior to
222 inclusion in the study. The study was registered in the German clinical trial registry with the
223 registration number DRKS00021220.

224 Results

225 A total of 826 participants were screened for enrolment between the 2nd November and 4th
226 December 2020 across two study sites, and 767 (92.9%) participants gave written informed
227 consent. Of the 767 participants, 493 were enrolled in Heidelberg and 274 in Berlin. Two
228 participants were excluded after enrolment as the NMT swab was refused and four participants
229 were excluded during analysis due to invalid RT-PCR results, resulting in 761 participants
230 included in the analysis (Figure 1).

231 Table 1 shows the clinical and demographic characteristics of all enrolled participants. The mean
232 age of the participants was 38.5 years (SD, 14.2) with 52% female and 31.7% with comorbidities
233 (Table 1). Symptoms on the testing day were reported by 64% of participants, with an average
234 symptom duration of 3.9 days (SD 3.2). Supplementary a detailed overview with all reported
235 symptoms is found in Section (E) Table 1. All asymptomatic participants were recent high-risk
236 contacts. From a total of 472 symptomatic patients, 423 (89.6%) reported onset of symptoms
237 within the prior 7 days. A total of 146 (19.2%) participants had a positive *SARS-CoV-2* RT-PCR
238 result, leading to a positivity rate of 29.7% (81 participants) in Berlin and 13.3% (65 participants)
239 in Heidelberg. Of all symptomatic participants a total of 137 (28.2%) had a positive *SARS-CoV-2*
240 RT-PCR result whereas only 9 (3.3%) of the asymptomatic participants had a *SARS-CoV-2* RT-PCR
241 result. The median viral load was 7.26 log₁₀ *SARS-CoV2* RNA copies/ml, with Berlin and
242 Heidelberg differing only slightly (7.75 and 6.97, respectively). Seven tests resulted in an error
243 message by the LumiraDx™ device. Upon repeat from the same sample extraction buffer, all
244 samples yielded valid results and were included in the analysis. Almost all participants were able

245 to perform the self-sampling without issues, with only 8 participants (1.1%) minorly deviating
246 from the sample collection protocol.

247 LumiraDx™ had an overall sensitivity of 82.2% (120 of 146 RT-PCR positives detected; 95% CI:
248 75.2%-87.5%) and a specificity of 99.3% (95% CI: 98.3-99.7%) (Figure 2). The performance varied
249 only slightly by site, with sensitivity of 84.6% (95% CI: 7.9%-91.4%) and 80.2% (95% CI: 70.3-
250 87.5%) and specificity of 99.3% (95% CI: 97.9- 99.7%) and 99.5% (95% CI: 97.1%-100%) in
251 Heidelberg and Berlin, respectively. The sensitivity was 86.9% (95% CI: 83.0%-93.8%) for
252 samples with a viral load ≥ 5 log₁₀ SARS-CoV2 RNA copies/ml and 93.8% (95% CI: 86.2%-97.3%)
253 for samples with a viral load ≥ 7 log₁₀ SARS-CoV2 RNA copies/ml (Figure 2). Sensitivity in
254 different categories of viral load compared to the RT-PCR results is shown in Figure 3. Similar,
255 for samples with cycle threshold (CT) values <25, the sensitivity was 92.6% (95% CI: 85.6%-
256 96.4%) and for those with a CT-value <30, the sensitivity was 90.2% (95% CI: 83.6%-94.3%)
257 (Figure 2). Correspondingly, the sensitivity was 62.7% (95% CI: 49.0%-74.7%) and 41.7% (95% CI:
258 24.5%-61.2%) for samples with a CT-value ≥ 25 and CT-value ≥ 30 (Figure 2). Supplementary
259 Table 2 (Section (F)) shows a detailed listing of the viral load, CT-value and Ag-RDT result for
260 each participant. Overall a moderate correlation was observed between the signal intensity
261 (measured by the cut-off-index (COI) values) of the LumiraDx™ device and viral load, except for
262 a few high viral load samples (5 with viral load >7 log₁₀ SARS-CoV2 RNA copies/ml) that scored a
263 low COI and were considered false-negative (supplement Section (G) Figure 2). Spearman rank
264 correlation coefficient was calculated to be 0.57 between COI and viral load.

265 Out of 758 participants, 272 (35.9%) were asymptomatic, high-risk contacts with nine RT-PCR
266 confirmed positive cases, resulting in a sensitivity of 77.8% with a wide confidence interval (95%

267 CI: 45.3%-93.7%). The sensitivity among symptomatic participants was 82.5% (95% CI: 75.3%-
268 87.9%) in comparison (Figure 2). The median viral load values of the asymptomatic cohort and
269 the symptomatic participants were 6.3 (IQR: 3.2-7.5) and 7.4 (IQR: 3.7-9.4) log₁₀ SARS-CoV2
270 RNA copies/ml, respectively. Figure 4 shows the sensitivity across asymptomatic and
271 symptomatic participants by viral load.

272 With respect to a possible impact of duration of illness, the overall sensitivity of the Ag-RDT was
273 found to increase slightly to 83.2% (95% CI: 75.9%-88.6%), when restricting the analysis to the
274 manufacturer recommended 12 days post symptom onset (N=461). Sensitivity was 86.4% (95%
275 CI: 79.1%-91.5%), with 102 of 118 RT-PCR positive cases detected, when symptom duration was
276 7 days or less, compared to 53.8% (95% CI: 29.1%-76.8%) for participants with a symptom
277 duration of 8-14 days.

278 **Discrepant analysis**

279 Sufficient sample volume was available to evaluate three out of three Ag-RDT positive but RT-
280 PCR negative cases (i.e., false positive) and only nine of 26 Ag-RDT negative but RT-PCR positive
281 cases (i.e., false negative) with an RT-PCR from the antigen buffer (thus 17 false-negative
282 samples could not be retested). All but two out of nine false negatives tested negative. The two-
283 testing positive on RT-PCR from the buffer showed a viral load likely below the analytical
284 sensitivity of LumiraDx™ (4.5 and 2.6 log₁₀ SARS-CoV2 RNA copies/ml; supplement Section (H)
285 Table 3).

286 **Analytical sensitivity**

287 To test the analytical sensitivity of LumiraDx™, a head-to-head comparison with Abbott PanBio
288 (Chicago, Illinois, USA) and SD Biosensor Standard Q (Gyeonggi-do, Korea), using in vitro-
289 propagated, live virus was employed. For this analysis, we tested the BavPat1 isolate produced
290 in two different cell lines (VeroE6 and Calu-3) as well as an additional patient isolate (HD
291 isolate). This analysis showed LumiraDx™ to have superior sensitivity to the two lateral flow
292 assays (Figure 5) across the three tested viruses. The analytical limit of detection was estimated
293 in the range of 2.1-55.6 PFU for LumiraDx™ which compared to 52.9 – 1,428.6 PFU and 8.8 -
294 238.1 PFU for the Abbott PanBio and SD Biosensor Standard Q, respectively. Of note, we
295 observed an overall lower sensitivity in detecting *SARS-CoV-2* produced in Calu-3 cells compared
296 to VERO cell stocks, which likely reflects higher levels of specific infectivity in virus isolated from
297 Calu-3 cells.

298 **Exclusivity testing**

299 No cross-reactivity was detected among a wide array of respiratory pathogens and commensals
300 tested, including the endemically circulating human coronaviruses. Detailed results of the
301 exclusivity testing are reported in Table 4 in Section (I) in the supplementary material.

302 **System Usability Scale (SUS) and Ease-of-Use Assessment (EoU)**

303 In the SUS, the LumiraDx™ scored 65 out of 100 points. The system was considered easy to use
304 without much training required. However, the test device is not suitable for batch testing. The
305 throughput within eight hour working shifts is a maximum of 24 tests per device, as only one
306 sample can be processed at a time and the device requires 12 minutes analysis time, in addition
307 to a 5-minute disinfection and drying procedure. A total storage time of five hours after sample

308 extraction allows for testing to be organized sequentially and most likely capture the maximal
309 throughput in a day (supplement Section (J) Figure 3 System Usability Score and Ease-of-Use
310 assessment results).

311 Discussion

312 This multi-centre clinical diagnostic accuracy study demonstrates a high sensitivity of 82.2% and
313 an excellent specificity of 99.3% for the evaluated LumiraDx™ microfluidic immunofluorescence
314 test. For participants with high viral load ($\geq 7 \log_{10}$ SARS-CoV2 RNA copies/ml) who are
315 presumably responsible for most secondary transmission, the test showed an even higher
316 sensitivity (93.8%) (13). The assay detected most positive cases within the first week of
317 symptoms, with a sensitivity of 86.4% (95% CI: 79.1%-91.5%). The analytical sensitivity was
318 excellent and surpassed that of other Ag-RDTs.

319 The clinical sensitivity of the LumiraDx™ in this study was not better than well performing lateral
320 flow assays that can be read with the naked eye in other studies (4, 5). The two WHO-
321 recommended Ag-RDTs, the SD Biosensor Standard Q and Abbott PanBio demonstrated
322 sensitivities ranging from 76.6-85.0% in our studies preceding this study (4, 14). However, as we
323 were not able to perform the tests head-to-head to allow a direct comparison, the differences
324 may be attributable to different phases of the pandemic with different test-positive ratios.
325 Although the test-positive ratio during the LumiraDx™ study was higher, absolute viral load and
326 viral load distribution were similar in our PanBio study that immediately preceded this study (4).

327 Another explanation for the lack of superior clinical sensitivity for LumiraDx™ could be the use
328 of NMT sampling in contrast to NP sampling for the aforementioned lateral flow assays as NP
329 sampling remains the gold standard (15). To what extent, however, the NMT sampling, the
330 manufacturer recommended sample type, reduces sensitivity is unclear. A recent Swedish study
331 suggested a reduction of 3% with NMT sampling for LumiraDx™, while a head-to head study in
332 our hands with another Ag-RDT showed largely equivalent performance (15-17). Also, important

333 to note is that the manufacturer recommended professional-collected NMT sampling while we
334 asked our study participants to self-collect their sample under professional supervision.
335 However, none of the false-negative samples in our study had observed deviations from the
336 optimal sampling procedure, therefore, though self-collection is not recommended by the
337 supplier and could have introduced variability, this is unlikely to have been the case. Also, recent
338 data from other studies comparing observed self- and professional-swab sampling shows this to
339 be unlikely as a source of large variability (16).

340 Nevertheless, inter-sample variability or differing distribution of virus in the nasal area during
341 the illness course could account for some false negative results, as supported by the two
342 samples in which virus was identified in very low amounts when antigen buffer was retested by
343 RT-PCR, while the viral load was high in the NP sample used for RT-PCR routine testing.

344 Our study shows a substantially lower clinically sensitivity than the study by Drain et al. (7).
345 While detailed comparisons are limited without access to the data of the Drain study, we would
346 consider the participant populations to be similar, apart from the fact that we had double the
347 percentage of asymptomatic participants. Another important difference of note is in the swabs
348 used. While the study by Drain et al. utilized a flocked swab, we utilized a standard rayon swab,
349 supplied by the manufacturer, which might contribute to less virus being captured in our study
350 (18).

351 The analytical results of the study confirm the claim of the manufacturer to have superior
352 sensitivity over the two other Ag-RDTs studied. Importantly, values obtained for the PanBio and
353 Standard Q in our study were similar to previous studies (19). Reasons for the high analytical
354 sensitivity not translating into high clinical sensitivity could relate to problems in the extraction

355 of the virus. However, the samples with high viral load that went undetected did not have any
356 particular characteristics (consistency, blood contamination), leaving the reasons for the
357 possible extraction problems unexplained. Another consideration could be immune escape due
358 to viral variants not recognized by the antibodies included in the test. This could explain variable
359 performance between two geographically distinct sites (in the Pacific North West of the USA in
360 the study by Drain et al. (7) and Germany). However, this appears very unlikely given the
361 multiple antibodies used in the test that target the nucleocapsid, which is a rather conserved
362 target even in recent strain variants (20). While a hook or prozone effect could be considered, it
363 appears unlikely in light of the samples type and has not been shown in prior experiments by
364 the manufacturer ([https://www.lumiradx.com/uk-en/what-we-do/diagnostics/test-
365 technology/antigen-test](https://www.lumiradx.com/uk-en/what-we-do/diagnostics/test-technology/antigen-test)). Thus, further studies are needed to explain the lower clinical
366 sensitivity of LumiraDx™ for some high viral load samples and the differences observed in
367 clinical and analytical sensitivity.

368 Nevertheless, it is to note, that the RT-PCR reference standard also has its limitations, as it is not
369 always a meaningful test when considering viable virus and risk of transmission (21). This is also
370 demonstrated by a recent study of an Ag-RDT in the USA, where the sensitivity was 92.6% in
371 symptomatic individuals when compared to viral culture versus 64.2% when compared to RT-
372 PCR (22). Thus, using the RT-PCR reference standard, we might have underestimated the
373 performance of the Ag-RDT when it comes to detection of viable virus.

374 We also acknowledge that the Lumira assay is only recommended for symptomatic patients.
375 Sensitivity was slightly higher among symptomatic patients (82.5%, 95% CI:75.3%-87.9%) as
376 compared to asymptomatic individuals (77.8%, 45.3%-93.7%), with overlapping confidence

377 intervals. This was to be expected from the lower viral load observed in the limited number of
378 asymptomatic positive cases. As cohort studies have shown the viral load kinetics between
379 asymptomatic and symptomatic infections to be similar, the findings of the lower viral load and
380 thus lower sensitivity observed in our study is most likely attributable to chance or to capturing
381 asymptomatic patients too early (maybe also prior to symptom development). Further need for
382 studies remain to better understand the performance in asymptomatic patients (23).

383 The excellent clinical specificity of the LumiraDx™ was confirmed by the analytical exclusivity
384 testing. Our findings indicate no cross-reactivity with the eleven tested pathogens or
385 commensals that would lead to false-positive Ag-RDT results. Assuming a SARS-CoV-2
386 prevalence of 1%, a test with the performance of the LumiraDx™ would result in a positive
387 predictive value (PPV) of 45.8% and a negative predictive value (NPV) of 99.8%. At a prevalence
388 of 3%, PPV would be 78.7% and NPV 99.5%.

389 The NMT sampling was considered highly favourable based on participants feedback in
390 comparison to the NP sampling. In addition, NMT self-sampling under professional supervision
391 would enable a higher sampling throughput, requiring fewer medical personnel and less
392 protective equipment used (e.g., the sampling could be observed through a window). Another
393 very favourable aspect of the test is the possibility for results to be reported automatically and
394 recorded digitally to be uploaded in information systems, which is an important characteristic
395 when it comes to surveillance and supply chain management. On the other hand, the device-
396 based assay does not allow for batch testing and has a limited throughput. Thus, our
397 observations show the LumiraDx™ to likely be most useful in an environment where persons to
398 be tested arrive over time, such as a medical office or emergency room. The device-based

399 LumiraDx™ system may also lend itself to simultaneous testing for several respiratory pathogens
400 from the same patient sample, which could facilitate the workup of individuals presenting with
401 non-specific respiratory symptoms, e.g., during the influenza season.

402 Overall, our study has several strengths. The study sites in Heidelberg and Berlin enrolled
403 participants representative of the current pandemic observed in Germany. The study
404 participants represented the age groups above 18 most commonly presenting for testing in an
405 ambulatory setting and including asymptomatic and symptomatic participants across the two
406 study sites, making the findings generalizable to ambulatory test settings across Germany. The
407 accuracy of the Ag-RDT was evaluated using several measures, including clinical accuracy,
408 analytical sensitivity, and exclusivity. In addition, the ease-of-use assessment especially
409 designed for this study, in combination with the standardized SUS, emphasized important points
410 regarding the operationalization of the test. Finally, this study was conducted in point-of-care
411 settings, representing the general diagnostic challenges of near patient testing.

412 However, our study also has limitations. The population was preselected by the local health
413 department's testing criteria based on national guidelines. As pandemic dynamics change, these
414 criteria are regularly updated, yet no significant differences were observed in enrolled study
415 population groups over the study time in terms of comparability. The sub-analyses by Ct-value
416 have limited comparability as three different RT-PCR standards were used for this study, using
417 different assay targets, reagents, and technical equipment. To account for possible variability
418 across tests in Ct-values, viral load was calculated using a standardized calibrated method and
419 used for the comparisons.

420 In conclusion, we demonstrate that the LumiraDx™ assay has comparable clinical sensitivity and
421 higher analytical sensitivity than WHO-approved lateral-flow Ag-RDTs, paired with excellent
422 specificity and operational characteristics suitable for low-throughput settings.

423 **Acknowledgments**

424 Angelika Sandritter, Alexander Syring, and the KTS company performing the routine testing at

425 the Heidelberg site

426 **Study Team**

Department of Public Health Rhein Neckar Region, Heidelberg, Germany	Dr. K. Assaad,
	Dr. A. Fuhs
	C. Harter
	C. Schulze
	G. Schmitt
Division of Clinical Tropical Medicine, Heidelberg University Hospital, Germany	Anja Klemmer
	Rico Müller
	Martina Fink
	Mathilde Fougereau
	Maximilian Schirmer
	Annika Small
	Matthias Meinschmidt
	Valerie Dürr
	Alina Schuckert
	Ann-Kathrin Backes
	Salome Steinke
	Henrik Ellinghaus
	Loai Abutaima
Institute of Tropical Medicine and International Health, Charité – Universitätsmedizin Berlin, Berlin, Germany	Mandy Kollatzsch
	Mia Wintel
	Franka Kausch
	Franziska Hommes
	Alisa Bölke
	Julian Bernhard
	Claudia Hülso
Elisabeth Linzbach	
Medical Directorate, Charité – Universitätsmedizin Berlin, Berlin, Germany	Heike Rössig
Institute of Tropical Medicine and International Health, Charité – Universitätsmedizin Berlin, Berlin, Germany	Maximilian Gertler
Charité Comprehensive Cancer Center, Charité – Universitätsmedizin Berlin, Berlin, Germany	Susen Burock
Department of Pediatric Surgery, Charité – Universitätsmedizin	Katja von dem Busche

Berlin, Berlin, Germany	
Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy, Institute of Clinical Pharmacology and Toxicology, Charité – Universitätsmedizin Berlin, Berlin, Germany	Stephanie Patberg

427

428 **Funding**

429 The study was supported by the Ministry of Science, Research and Arts of the State of Baden-
430 Wuerttemberg, Germany and internal funds from the Heidelberg University Hospital and
431 University Hospital Charité - Universitätsmedizin Berlin as well as grants from UK Department of
432 International Development (DFID, recently replaced by FCMO), grants from World Health
433 Organization (WHO), grants from Unitaid to Foundation of New Diagnostics (FIND). The testing
434 devices and all components were provided by the manufacturer. T.C.J. is in part funded through
435 NIAID-NIH CEIRS contract HHSN272201400008C. The manufacturer and funders had no input
436 into the study protocol, the analysis or interpretation of the results. The corresponding author
437 had access to all data at all time.


438 **References**

- 439 1. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S,
440 Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S,
441 Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C,
442 Koopmans MP, Drosten C. 2020. Detection of 2019 novel coronavirus (2019-nCoV) by
443 real-time RT-PCR. *Euro Surveill* 25.
- 444 2. Holt E. 2020. Slovakia to test all adults for SARS-CoV-2. *The Lancet* 396:1386-1387.
- 445 3. Berger A, Ngo Nsoga M-T, Perez Rodriguez FJ, Abi Aad Y, Sattonnet P, Gayet-Ageron A,
446 Jaksic C, Torriani G, Boehm E, Kronig I, Sacks JA, de Vos M, Jacquerioz-Bausch F, Chappuis
447 F, Kaiser L, Schibler M, Eckerle I. 2020. Diagnostic accuracy of two commercial SARS-CoV-
448 2 Antigen-detecting rapid tests at the point of care in community-based testing centers.
449 medRxiv doi:10.1101/2020.11.20.20235341:2020.11.20.20235341.
- 450 4. Krüger LJ, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, Schnitzler P,
451 Kräusslich HG, Nikolai O, Lindner AK, Mockenhaupt FP, Seybold J, Corman VM, Drosten
452 C, Pollock NR, Knorr B, Welker A, de Vos M, Sacks JA, Denkinger CM. 2020. Evaluation of
453 the accuracy and ease-of-use of Abbott PanBio - A WHO emergency use listed, rapid,
454 antigen-detecting point-of-care diagnostic test for SARS-CoV-2. medRxiv
455 doi:10.1101/2020.11.27.20239699:2020.11.27.20239699.
- 456 5. Krüger LJ, Gaeddert M, Köppel L, Brümmer LE, Gottschalk C, Miranda IB, Schnitzler P,
457 Kräusslich HG, Lindner AK, Nikolai O, Mockenhaupt FP, Seybold J, Corman VM, Drosten
458 C, Pollock NR, Cubas-Atienzar AI, Kontogianni K, Collins A, Wright AH, Knorr B, Welker A,
459 de Vos M, Sacks JA, Adams ER, Denkinger CM. 2020. Evaluation of the accuracy, ease of

- 460 use and limit of detection of novel, rapid, antigen-detecting point-of-care diagnostics for
461 SARS-CoV-2. medRxiv doi:10.1101/2020.10.01.20203836:2020.10.01.20203836.
- 462 6. Basiri A, Heidari A, Nadi MF, Fallahy MTP, Nezamabadi SS, Sedighi M, Saghadzadeh A,
463 Rezaei N. 2020. Microfluidic devices for detection of RNA viruses. *Reviews in medical*
464 *virology* doi:10.1002/rmv.2154:e2154-e2154.
- 465 7. Drain PK, Ampajwala M, Chappel C, Gvozden AB, Hoppers M, Wang M, Rosen R, Young S,
466 Zissman E, Montano M. 2020. A rapid, high-sensitivity SARS-CoV-2 nucleocapsid
467 immunoassay to aid diagnosis of acute COVID-19 at the point of care. medRxiv
468 doi:10.1101/2020.12.11.20238410:2020.12.11.20238410.
- 469 8. Cohen JF, Korevaar DA, Altman DG, Bruns DE, Gatsonis CA, Hooft L, Irwig L, Levine D,
470 Reitsma JB, de Vet HCW, Bossuyt PMM. 2016. STARD 2015 guidelines for reporting
471 diagnostic accuracy studies: explanation and elaboration. *BMJ Open* 6:e012799.
- 472 9. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. 2009. Research electronic
473 data capture (REDCap)--a metadata-driven methodology and workflow process for
474 providing translational research informatics support. *J Biomed Inform* 42:377-81.
- 475 10. Klein S, Cortese M, Winter SL, Wachsmuth-Melm M, Neufeldt CJ, Cerikan B, Stanifer ML,
476 Boulant S, Bartenschlager R, Chlanda P. 2020. SARS-CoV-2 structure and replication
477 characterized by in situ cryo-electron tomography. *Nature Communications* 11:5885.
- 478 11. Bangor A, Kortum PT, Miller JT. 2008. An Empirical Evaluation of the System Usability
479 Scale. *International Journal of Human-Computer Interaction* 24:574-594.
- 480 12. Altman DG, Bland JM. 1994. Diagnostic tests. 1: Sensitivity and specificity. *BMJ* 308:1552.

- 481 13. Meyerowitz EA, Richterman A, Gandhi RT, Sax PE. 2020. Transmission of SARS-CoV-2: A
482 Review of Viral, Host, and Environmental Factors. *Annals of internal medicine*
483 doi:10.7326/M20-5008:M20-5008.
- 484 14. Lindner AK, Nikolai O, Rohardt C, Kausch F, Wintel M, Gertler M, Burock S, Horig M,
485 Bernhard J, Tobian F, Gaeddert M, Lainati F, Corman VM, Jones TC, Sacks JA, Seybold J,
486 Denkinger CM, Mockenhaupt FP. 2021. SARS-CoV-2 patient self-testing with an antigen-
487 detecting rapid test: a head-to-head comparison with professional testing. *medRxiv*
488 doi:10.1101/2021.01.06.20249009:2021.01.06.20249009.
- 489 15. Scandinavian evaluation of laboratory equipment for point of care testing. 2020.
490 LumiraDx: A system for detection of SARS-CoV-2 antigen and antibodies, PT (INR) and D-
491 Dimer manufactured by LumiraDx UK Ltd - An evaluation of the detection of SARS-CoV-2
492 antigen.
- 493 16. Lindner AK, Nikolai O, Kausch F, Wintel M, Hommes F, Gertler M, Kruger LJ, Gaeddert M,
494 Tobian F, Lainati F, Koppel L, Seybold J, Corman VM, Drosten C, Hofmann J, Sacks JA,
495 Mockenhaupt FP, Denkinger CM. 2020. Head-to-head comparison of SARS-CoV-2
496 antigen-detecting rapid test with self-collected anterior nasal swab versus professional-
497 collected nasopharyngeal swab. *Eur Respir J* doi:10.1183/13993003.03961-2020.
- 498 17. Lindner AK, Nikolai O, Rohardt C, Burock S, Hülso C, Bölke A, Gertler M, Krüger LJ,
499 Gaeddert M, Tobian F, Lainati F, Seybold J, Jones TC, Hofmann J, Sacks JA, Mockenhaupt
500 FP, Denkinger CM. 2021. Head-to-head comparison of SARS-CoV-2 antigen-detecting
501 rapid test with professional-collected nasal versus nasopharyngeal swab. *European*
502 *Respiratory Journal* doi:10.1183/13993003.04430-2020:2004430.


- 503 18. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. 2020. Performance of Saliva,
504 Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A
505 Systematic Review and Meta-analysis. medRxiv
506 doi:10.1101/2020.11.12.20230748:2020.11.12.20230748.
- 507 19. Corman VM, Haage VC, Bleicker T, Schmidt ML, Mühlemann B, Zuchowski M, Jó Lei WK,
508 Tscheak P, Möncke-Buchner E, Müller MA, Krumbholz A, Drexler JF, Drosten C. 2020.
509 Comparison of seven commercial SARS-CoV-2 rapid Point-of-Care Antigen tests. medRxiv
510 doi:10.1101/2020.11.12.20230292:2020.11.12.20230292.
- 511 20. Haynes WA, Kamath K, Lucas C, Shon J, Iwasaki A. 2021. Impact of B.1.1.7 variant
512 mutations on antibody recognition of linear SARS-CoV-2 epitopes. medRxiv
513 doi:10.1101/2021.01.06.20248960:2021.01.06.20248960.
- 514 21. Sun J, Xiao J, Sun R, Tang X, Liang C, Lin H, Zeng L, Hu J, Yuan R, Zhou P, Peng J, Xiong Q,
515 Cui F, Liu Z, Lu J, Tian J, Ma W, Ke C. 2020. Prolonged Persistence of SARS-CoV-2 RNA in
516 Body Fluids. *Emerging Infectious Disease journal* 26:1834.
- 517 22. Prince-Guerra J AO, Nolen L, et al. 2020. Evaluation of Abbott BinaxNOW Rapid Antigen
518 Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites — Pima County,
519 Arizona. *MMWR Morb Mortal Wkly Rep* 2021 70:100–105.
- 520 23. Kissler SM, Fauver JR, Mack C, Olesen SW, Tai C, Shiue KY, Kalinich CC, Jednak S, Ott IM,
521 Vogels CBF, Wohlgemuth J, Weisberger J, DiFiori J, Anderson DJ, Mancell J, Ho DD,
522 Grubaugh ND, Grad YH. 2020. SARS-CoV-2 viral dynamics in acute infections. medRxiv
523 doi:10.1101/2020.10.21.20217042:2020.10.21.20217042.
- 524



525 **Figure 1. Study Flow**

		Overall Total N= 761	Heidelberg Total N= 488	Berlin Total N= 273
Age in years Information available on N=761	Mean (SD)	38.5 (14.2)	40.1 (14.9)	35.8 (12.3)
Gender Information available on N=759	Female N (%)	396 (52.2)	266 (54.7)	130 (47.6)
BMI >25 Information available on N=703	N (%)	327 (46.5)	243 (50.2)	84 (38.4)
Comorbidities Information available on N=760	N (%)	241 (31.7)	183 (37.6)	58 (21.2)
Symptoms on Testing Day Information available on N= 758	N (%)	486 (64.1)	218 (44.8)	268 (98.2)
Duration of symptoms from day of testing in days Information available on N= 472	Mean (SD)	3.9 (3.2)	3.7 (3.7)	4.1 (2.7)
Prior test performed and negative Information available on N= 695	Yes N (%)	86 (12.4)	80 (16.6)	6 (2.8)
RT-PCR positives	N (%)	146 (19.2)	65 (13.3)	81 (29.7)
Viral Load (log ₁₀ SARS-CoV2 RNA copies/ml) Information available on N= 146	Median (IQR)	7.3 (3.7-9.4)	7.0 (3.4-8.5)	7.8 (3.8-9.4)


526 **Table 1. Study population characteristics**




527

528 **Figure 2. Forest plot of sensitivity analysis overall and by subgroup for LumiraDx™**


529 n = number, TP = true positives, FN = false negatives, FP = false positives, TN = true negatives



530
531 **Figure 3. Sensitivity of LumiraDx™ compared to viral load for all RT-PCR positive participants**
532 Viral load unit: log₁₀ SARS-CoV2 RNA copies/ml



533
534 **Figure 4. LumiraDx™ results according to viral load by presence of symptoms and days since**
535 **symptom onset for all RT-PCR positive participants**
536 Viral load unit: log₁₀ SARS-CoV2 RNA copies/ml



537

538 **Figure 5. Analytical sensitivity of LumiraDx in comparison to Abbott PanBio and SD Biosensor**

539 **Standard Q**